Psychedelic stocks broke out in 2025 after RFK Jr's backing

Psychedelic drugmakers moved into the mainstream in 2025 amid regulatory easing and political backing tied to Robert F Kennedy Jr. Mind Medicine led in retail sentiment and cash runway, while Compass Pathways advanced closer to commercialisation. Both are positioned to tap a fast-growing mental health market with major unmet need.